PTCT.US PTC Therapeutics Inc

Healthcare Biotechnology USA Stocks
60.36 USD
Close of Nov 17, 2026
58.80 90.87
Market cap
USD 5.04B
P/E
-
P/B
1,743.27x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PTCT.US undervalued?

Graham number

The Graham number of PTC Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

PTC Therapeutics Inc fundamental analysis

No fundamental analysis for PTC Therapeutics Inc yet.

PTC Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and…

Full company profile